Is the platelet lowering activity of anagrelide mediated by its major metabolite 2-amino-5,6-dichloro-3,4-dihydroquinazoline (RL603)?
Jorge D
JD
Erusalimsky
Ying
Y
Hong
Richard
R
Franklin
D000818:Animals; D001792:Blood Platelets / Q000187:drug effects*; D002454:Cell Differentiation / Q000187:drug effects; D002478:Cells, Cultured / Q000166:cytology / Q000187:drug effects; D004285:Dogs; D006801:Humans; D008533:Megakaryocytes / Q000187:drug effects*; D051379:Mice; D008807:Mice, Inbred BALB C; D009363:Neoplasm Proteins; D010975:Platelet Aggregation Inhibitors / Q000493:pharmacokinetics / Q000494:pharmacology*; D011518:Proto-Oncogene Proteins / Q000187:drug effects / Q000235:genetics / Q000502:physiology; D011799:Quinazolines / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000633:toxicity; D011817:Rabbits; D051381:Rats; D017208:Rats, Wistar; D018121:Receptors, Cytokine; D053628:Receptors, Thrombopoietin; D013045:Species Specificity; D013921:Thrombocytopenia / Q000139:chemically induced; D013926:Thrombopoietin / Q000494:pharmacology; D014162:Transfection
C464519:2-amino-5,6-dichloro-3,4-dihydroquinazoline; D009363:Neoplasm Proteins; D010975:Platelet Aggregation Inhibitors; D011518:Proto-Oncogene Proteins; D011799:Quinazolines; D018121:Receptors, Cytokine; D053628:Receptors, Thrombopoietin; C082218:MPL protein, human; D013926:Thrombopoietin; C021139:anagrelide